Qi Chen

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 6

Top Topics

Combination Therapy

Prognostic Factors

Anti Inflammatory

Top Venues

British journal of cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Enliang Li, Jian Xu, Qi Chen, Xiaozhen Zhang, Xingyuan Xu, Jianpeng Sheng
Galectin-9 and PD-L1 antibody blockade combination therapy inhibits tumour progression in pancreatic cancer. Immunotherapy 15 (3) (2023)
Enliang Li, Jian Xu, Qi Chen, Xiaozhen Zhang, Xingyuan Xu, Jianpeng Sheng
Galectin-9 and PD-L1 antibody blockade combination therapy inhibits tumour progression in pancreatic cancer. Immunotherapy 15 (3) (2023)
Enliang Li, Jian Xu, Qi Chen, Xiaozhen Zhang, Xingyuan Xu, Jianpeng Sheng
Galectin-9 and PD-L1 antibody blockade combination therapy inhibits tumour progression in pancreatic cancer. Immunotherapy (2023)
Enliang Li, Jian Xu, Qi Chen, Xiaozhen Zhang, Xingyuan Xu, Jianpeng Sheng
Galectin-9 and PD-L1 antibody blockade combination therapy inhibits tumour progression in pancreatic cancer. Immunotherapy 15 (3) (2023)
Qi Chen, Jianxin Wang, Wei Chen, Qi Zhang, Tao Wei, Yue Zhou, Xingyuan Xu, Xueli Bai, Tingbo Liang
B7-H5/CD28H is a co-stimulatory pathway and correlates with improved prognosis in pancreatic ductal adenocarcinoma. Cancer science 110 (2) (2019)
Qi Chen, Jianxin Wang, Qi Zhang, Jingying Zhang, Yu Lou, Jiaqi Yang, Yiwen Chen, Tao Wei, Jian Zhang, Qihan Fu, Mao Ye, Xiaozhen Zhang, Xiaowei Dang, Tingbo Liang, Xueli Bai
Tumour cell-derived debris and IgG synergistically promote metastasis of pancreatic cancer by inducing inflammation via tumour-associated macrophages. British journal of cancer 121 (9) (2019)